This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chatterjee, K. Articles by Norman, A. Search for Related Content PubMed PubMed Citation Articles by Chatterjee, K. Articles by Norman, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Hazardous Substances DB HYDRALAZINE HYDROCHLORIDE

Circulation, Vol 54, 879-883, Copyright © 1976 by American Heart Association

ARTICLES

Oral hydralazine therapy for chronic refractory heart failure

K Chatterjee, WW Parmley, B Massie, B Greenberg, J Werner, S Klausner and A Norman

The hemodynamic effects of oral hydralazine were investigated in ten patients (nine in NYHA Class IV and one in Class III) with chronic refractory heart failure. With hemodynamic monitoring, adequate oral doses of hydralazine (50 or 75 mg) were determined and then administered every six hours. Hemodynamics were determined at 2-3, 6-8 and 24 hours on hydralazine therapy. Arterial pressure decreased slightly (5%) and systemic vascular resistance decreased significantly (42%). Cardiac and stroke volume index increased by 70 and 66%, respectively, without any significant change in heart rate, pulmonary capillary wedge or right atrial pressure. Hemodynamic improvement was associated with clinical improvement without a major complication. During the follow-up period of 3-7 months, seven of nine patients were in NYHA Class II and one in Class III. One other patient died suddenly six weeks after discharge. These findings suggest that hydralazine in an effective oral vasodilator for the treatment of refractory heart failure.

This article has been cited by other articles:

				M. S. Nieminen Pharmacological options for acute heart failure syndromes: current treatments and unmet needs Eur. Heart J. Suppl., April 1, 2005; 7(suppl_B): B20 - B24. [Abstract] [Full Text] [PDF]

				K. Chatterjee Heart Failure Therapy in Evolution Circulation, December 1, 1996; 94(11): 2689 - 2693. [Full Text]

				A. J. Manolis, C. Olympios, M. Sifaki, S. Handanis, M. Bresnahan, I. Gavras, and H. Gavras Suppressing Sympathetic Activation in Congestive Heart Failure : A New Therapeutic Strategy Hypertension, November 1, 1995; 26(5): 719 - 724. [Abstract] [Full Text]

				A. A. Losardo, N. A. Klein, N. Beer, J. A. Strom, J. P. Wexler, E. H. Sonnenblick, and W. H. Frishman Beneficial Effects of Sublingual Nifedipine in Patients with Ischemic Heart Disease and Depressed Left Ventricular Function Angiology, December 1, 1982; 33(12): 811 - 817. [Abstract] [PDF]

				R. M. Gunnar The Role of Vasodilating Agents in the Treatment of Chronic Heart Failure Angiology, August 1, 1980; 31(8): 526 - 532. [PDF]

				J. A. Franciosa Outflow Resistance as a Regulator of Left Ventricular Performance Angiology, May 1, 1978; 29(5): 393 - 401. [PDF]